Abstract
Important advances in our understanding of the relationships between adipokines, inflammation and the immune response have been achieved in the past 10 years. White adipose tissue has emerged as a highly dynamic organ that releases a plethora of immune and inflammatory mediators that are involved in numerous diseases, including not only rheumatic diseases such as rheumatoid arthritis, osteoarthritis and systemic lupus erythematosus, but also cardiovascular and metabolic complications that are frequently observed in rheumatic diseases. Our rapidly growing knowledge of adipokine biology is revealing the complexity of these amazing proteins, thereby redefining white adipose tissue as a key element of the inflammatory and immune response in rheumatic diseases. Adipokines exert potent modulatory actions on target tissues and cells involved in rheumatic disease, including cartilage, synovium, bone and various immune cells. In this Review, we describe the most recent advances in adipokine research in the context of rheumatic diseases, focusing primarily on leptin, adiponectin, visfatin and resistin, and also the potential role of newly identified adipokines such as chemerin, lipocalin 2 and serum amyloid A3.
Key Points
-
Adipose tissue, through the production of adipokines, is emerging as one of the major drivers of systemic and local inflammation in rheumatic diseases
-
Adipokines are produced predominantly by adipose tissue, but are also expressed intra-articularly by chondrocytes, synoviocytes and immune cells
-
Adipokines are emerging as modulators of rheumatic diseases by promoting and perpetuating inflammatory responses
-
Adipokine levels are associated with radiographic damage in patients with rheumatoid arthritis
-
Obesity and fat-mass dysfunction, characterized by aberrant adipokine expression, might be considered as one of the major risk factors for the development and progression of osteoarthritis
-
Therapeutic strategies aimed to counteract dysregulation of proinflammatory adipokine production could be effective in rheumatic diseases
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lago, F., Dieguez, C., Gomez-Reino, J. & Gualillo, O. Adipokines as emerging mediators of immune response and inflammation. Nat. Clin. Pract. Rheumatol. 3, 716–724 (2007).
Lee, S. W., Park, M. C., Park, Y. B. & Lee, S. K. Measurement of the serum leptin level could assist disease activity monitoring in rheumatoid arthritis. Rheumatol. Int. 27, 537–540 (2007).
Targonska-Stepniak, B., Majdan, M. & Dryglewska, M. Leptin serum levels in rheumatoid arthritis patients: relation to disease duration and activity. Rheumatol. Int. 28, 585–591 (2008).
Targonska-Stepniak, B., Dryglewska, M. & Majdan, M. Adiponectin and leptin serum concentrations in patients with rheumatoid arthritis. Rheumatol. Int. 30, 731–737 (2010).
Olama, S. M., Senna, M. K. & Elarman, M. Synovial/serum leptin ratio in rheumatoid arthritis: the association with activity and erosion. Rheumatol. Int. doi:10.1007/s00296-010-1698-5.
Rho, Y. H. et al. Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum. 60, 1906–1914 (2009).
Loeser, R. F. Systemic and local regulation of articular cartilage metabolism: where does leptin fit in the puzzle? Arthritis Rheum. 48, 3009–3012 (2003).
Popa, C. et al. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis. J. Rheumatol. 36, 724–730 (2009).
Derdemezis, C. S. et al. Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis. Fundam. Clin. Pharmacol. 23, 595–600 (2009).
Gonzalez-Gay, M. A. et al. Short-term effect of anti-TNF-alpha therapy on nitric oxide production in patients with severe rheumatoid arthritis. Clin. Exp. Rheumatol. 27, 452–458 (2009).
Engvall, I. L., Tengstrand, B., Brismar, K. & Hafstrom, I. Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. Arthritis Res. Ther. 12, R197 (2010).
Otero, M., Gomez Reino, J. J. & Gualillo, O. Synergistic induction of nitric oxide synthase type II: in vitro effect of leptin and interferon-γ in human chondrocytes and ATDC5 chondrogenic cells. Arthritis Rheum. 48, 404–409 (2003).
Otero, M., Lago, R., Lago, F., Reino, J. J. & Gualillo, O. Signalling pathway involved in nitric oxide synthase type II activation in chondrocytes: synergistic effect of leptin with interleukin-1. Arthritis Res. Ther. 7, R581–R591 (2005).
Otero, M. et al. Phosphatidylinositol 3-kinase, MEK-1 and p38 mediate leptin/interferon-gamma synergistic NOS type II induction in chondrocytes. Life Sci. 81, 1452–1460 (2007).
Kitahara, K., Kusunoki, N., Kakiuchi, T., Suguro, T. & Kawai, S. Adiponectin stimulates IL-8 production by rheumatoid synovial fibroblasts. Biochem. Biophys. Res. Commun. 378, 218–223 (2009).
Tong, K. M. et al. Leptin induces IL-8 expression via leptin receptor, IRS-1, PI3K, Akt cascade and promotion of NF-κB/p300 binding in human synovial fibroblasts. Cell. Signal. 20, 1478–1488 (2008).
Notley, C. A. & Ehrenstein, M. R. The yin and yang of regulatory T cells and inflammation in RA. Nat. Rev. Rheumatol. 6, 572–577 (2010).
Matarese, G., Leiter, E. H. & La Cava, A. Leptin in autoimmunity: many questions, some answers. Tissue Antigens 70, 87–95 (2007).
Matarese, G., Procaccini, C., De Rosa, V., Horvath, T. L. & La Cava, A. Regulatory T cells in obesity: the leptin connection. Trends Mol. Med. 16, 247–256 (2010).
Procaccini, C. et al. An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity 33, 929–941 (2010).
De Rosa, V. et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity 26, 241–255 (2007).
Vuolteenaho, K. et al. Leptin enhances synthesis of proinflammatory mediators in human osteoarthritic cartilage—mediator role of NO in leptin-induced PGE2, IL-6, and IL-8 production. Mediators Inflamm. 2009, 345838 (2009).
Griffin, T. M., Huebner, J. L., Kraus, V. B. & Guilak, F. Extreme obesity due to impaired leptin signaling in mice does not cause knee osteoarthritis. Arthritis Rheum. 60, 2935–2944 (2009).
Pallu, S. et al. Obesity affects the chondrocyte responsiveness to leptin in patients with osteoarthritis. Arthritis Res. Ther. 12, R112 (2010).
Dumond, H. et al. Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum. 48, 3118–3129 (2003).
Karsenty, G. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab. 4, 341–348 (2006).
Mutabaruka, M. S., Aoulad Aissa, M., Delalandre, A., Lavigne, M. & Lajeunesse, D. Local leptin production in osteoarthritis subchondral osteoblasts may be responsible for their abnormal phenotypic expression. Arthritis Res. Ther. 12, R20 (2010).
Lago, F. et al. Cardiometabolic comorbidities and rheumatic diseases: focus on the role of fat mass and adipokines. Arthritis Care Res. (Hoboken) doi:10.1002/acr.20488.
Hahn, B. H. et al. Pro-inflammatory high-density lipoproteins and atherosclerosis are induced in lupus-prone mice by a high-fat diet and leptin. Lupus 19, 913–917 (2010).
Ehling, A. et al. The potential of adiponectin in driving arthritis. J. Immunol. 176, 4468–4478 (2006).
Schaffler, A. et al. Adipocytokines in synovial fluid. JAMA 290, 1709–1710 (2003).
Otero, M. et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann. Rheum. Dis. 65, 1198–1201 (2006).
Neumeier, M. et al. Different effects of adiponectin isoforms in human monocytic cells. J. Leukoc. Biol. 79, 803–808 (2006).
Ebina, K. et al. Serum adiponectin concentrations correlate with severity of rheumatoid arthritis evaluated by extent of joint destruction. Clin. Rheumatol. 28, 445–451 (2009).
Giles, J. T., Allison, M., Bingham, C. O. 3rd, Scott, W. M. Jr & Bathon, J. M. Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis. Arthritis Rheum. 61, 1248–1256 (2009).
Nagashima, T. et al. Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis. J. Rheumatol. 35, 936–938 (2008).
Tang, C. H., Chiu, Y. C., Tan, T. W., Yang, R. S. & Fu, W. M. Adiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38, and NF-κB pathway. J. Immunol. 179, 5483–5492 (2007).
Choi, H. M. et al. Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators. Arthritis Res. Ther. 11, R161 (2009).
Kusunoki, N. et al. Adiponectin stimulates prostaglandin E2 production in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 62, 1641–1649 (2010).
Frommer, K. W. et al. Adiponectin-mediated changes in effector cells involved in the pathophysiology of rheumatoid arthritis. Arthritis Rheum. 62, 2886–2899 (2010).
Lago, R. et al. A new player in cartilage homeostasis: adiponectin induces nitric oxide synthase type II and pro-inflammatory cytokines in chondrocytes. Osteoarthritis Cartilage 16, 1101–1109 (2008).
Kang, E. H. et al. Adiponectin is a potential catabolic mediator in osteoarthritis cartilage. Arthritis Res. Ther. 12, R231 (2010).
Gómez, R. et al. Adiponectin and leptin increase IL-8 production in human chondrocytes. Ann. Rheum. Dis. doi:10.1136/ard.2010.145672.
Klein-Wieringa, I. R. et al. The infrapatellar fat pad of patients with osteoarthritis has an inflammatory phenotype. Ann. Rheum. Dis. 70, 851–857 (2011).
Ushiyama, T., Chano, T., Inoue, K. & Matsusue, Y. Cytokine production in the infrapatellar fat pad: another source of cytokines in knee synovial fluids. Ann. Rheum. Dis. 62, 108–112 (2003).
Distel, E. et al. The infrapatellar fat pad in knee osteoarthritis: an important source of interleukin-6 and its soluble receptor. Arthritis Rheum. 60, 3374–3377 (2009).
Laurberg, T. B. et al. Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls. J. Rheumatol. 36, 1885–1891 (2009).
Filkova, M. et al. Increased serum adiponectin levels in female patients with erosive compared with non-erosive osteoarthritis. Ann. Rheum. Dis. 68, 295–296 (2009).
Honsawek, S. & Chayanupatkul, M. Correlation of plasma and synovial fluid adiponectin with knee osteoarthritis severity. Arch. Med. Res. 41, 593–598 (2010).
Hao, D. et al. Synovial fluid level of adiponectin correlated with levels of aggrecan degradation markers in osteoarthritis. Rheumatol. Int. doi:10.1007/s00296-010-1516-0.
Gandhi, R., Takahashi, M., Smith, H., Rizek, R. & Mahomed, N. N. The synovial fluid adiponectin-leptin ratio predicts pain with knee osteoarthritis. Clin. Rheumatol. 29, 1223–1228 (2010).
Forsblad d'Elia, H., Pullerits, R., Carlsten, H. & Bokarewa, M. Resistin in serum is associated with higher levels of IL-1Ra in post-menopausal women with rheumatoid arthritis. Rheumatology (Oxford) 47, 1082–1087 (2008).
Senolt, L. et al. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann. Rheum. Dis. 66, 458–463 (2007).
Gonzalez-Gay, M. A. et al. Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 26, 311–316 (2008).
Lee, J. H. et al. Resistin is elevated following traumatic joint injury and causes matrix degradation and release of inflammatory cytokines from articular cartilage in vitro. Osteoarthritis Cartilage 17, 613–620 (2009).
Zhang, Z. et al. Resistin induces expression of proinflammatory cytokines and chemokines in human articular chondrocytes via transcription and messenger RNA stabilization. Arthritis Rheum. 62, 1993–2003 (2010).
Brentano, F. et al. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum. 56, 2829–2839 (2007).
Busso, N. et al. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One 3, e2267 (2008).
Gosset, M. et al. Crucial role of visfatin/pre-B cell colony-enhancing factor in matrix degradation and prostaglandin E2 synthesis in chondrocytes: possible influence on osteoarthritis. Arthritis Rheum. 58, 1399–1409 (2008).
Wittamer, V. et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J. Exp. Med. 198, 977–985 (2003).
Zabel, B. A. et al. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J. Biol. Chem. 280, 34661–34666 (2005).
Bozaoglu, K. et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 148, 4687–4694 (2007).
Luangsay, S. et al. Mouse ChemR23 is expressed in dendritic cell subsets and macrophages, and mediates an anti-inflammatory activity of chemerin in a lung disease model. J. Immunol. 183, 6489–6499 (2009).
Kralisch, S. et al. Interleukin-1β induces the novel adipokine chemerin in adipocytes in vitro. Regul. Pept. 154, 102–106 (2009).
Triebel, S., Blaser, J., Reinke, H. & Tschesche, H. A 25 kDa α2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett. 314, 386–388 (1992).
Hvidberg, V. et al. The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett. 579, 773–777 (2005).
Flower, D. R. The lipocalin protein family: structure and function. Biochem. J. 318, 1–14 (1996).
Devireddy, L. R., Teodoro, J. G., Richard, F. A. & Green, M. R. Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science 293, 829–834 (2001).
Chu, S. T., Lin, H. J., Huang, H. L. & Chen, Y. H. The hydrophobic pocket of 24p3 protein from mouse uterine luminal fluid: fatty acid and retinol binding activity and predicted structural similarity to lipocalins. J. Pept. Res. 52, 390–397 (1998).
Yang, J. et al. An iron delivery pathway mediated by a lipocalin. Mol. Cell 10, 1045–1056 (2002).
Cowland, J. B. & Borregaard, N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics 45, 17–23 (1997).
Yan, Q. W. et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 56, 2533–2540 (2007).
Jiang, W., Constante, M. & Santos, M. M. Anemia upregulates lipocalin 2 in the liver and serum. Blood Cells Mol. Dis. 41, 169–174 (2008).
Goetz, D. H. et al. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol. Cell 10, 1033–1043 (2002).
Sommer, G. et al. Lipocalin-2 is induced by interleukin-1β in murine adipocytes in vitro. J. Cell Biochem. 106, 103–108 (2009).
Owen, H. C., Roberts, S. J., Ahmed, S. F. & Farquharson, C. Dexamethasone-induced expression of the glucocorticoid response gene lipocalin 2 in chondrocytes. Am. J. Physiol. Endocrinol. Metab. 294, E1023–E1034 (2008).
Gupta, K., Shukla, M., Cowland, J. B., Malemud, C. J. & Haqqi, T. M. Neutrophil gelatinase-associated lipocalin is expressed in osteoarthritis and forms a complex with matrix metalloproteinase 9. Arthritis Rheum. 56, 3326–3335 (2007).
Wilson, R., Belluoccio, D., Little, C. B., Fosang, A. J. & Bateman, J. F. Proteomic characterization of mouse cartilage degradation in vitro. Arthritis Rheum. 58, 3120–3131 (2008).
Yamamoto, K. & Migita, S. Complete primary structures of two major murine serum amyloid A proteins deduced from cDNA sequences. Proc. Natl Acad. Sci. USA 82, 2915–2919 (1985).
Lowell, C. A., Stearman, R. S. & Morrow, J. F. Transcriptional regulation of serum amyloid A gene expression. J. Biol. Chem. 261, 8453–8461 (1986).
de Beer, M. C., Beach, C. M., Shedlofsky, S. I. & de Beer, F. C. Identification of a novel serum amyloid A protein in BALB/c mice. Biochem. J. 280, 45–49 (1991).
Kluve-Beckerman, B., Drumm, M. L. & Benson, M. D. Nonexpression of the human serum amyloid A three (SAA3) gene. DNA Cell Biol. 10, 651–661 (1991).
Kluve-Beckerman, B. & Song, M. Genes encoding human serum amyloid A proteins SAA1 and SAA2 are located 18 kb apart in opposite transcriptional orientations. Gene 159, 289–290 (1995).
Reigstad, C. S., Lunden, G. O., Felin, J. & Backhed, F. Regulation of serum amyloid A3 (SAA3) in mouse colonic epithelium and adipose tissue by the intestinal microbiota. PLoS One 4, e5842 (2009).
Fasshauer, M. et al. Serum amyloid A3 expression is stimulated by dexamethasone and interleukin-6 in 3T3-L1 adipocytes. J. Endocrinol. 183, 561–567 (2004).
Lin, Y. et al. Hyperglycemia-induced production of acute phase reactants in adipose tissue. J. Biol. Chem. 276, 42077–42083 (2001).
Pickup, J. C., Mattock, M. B., Chusney, G. D. & Burt, D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40, 1286–1292 (1997).
Han, C. Y. et al. Adipocyte-derived serum amyloid A3 and hyaluronan play a role in monocyte recruitment and adhesion. Diabetes 56, 2260–2273 (2007).
Sommer, G. et al. The adipokine SAA3 is induced by interleukin-1β in mouse adipocytes. J. Cell. Biochem. 104, 2241–2247 (2008).
Vallon, R. et al. Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J. Immunol. 166, 2801–2807 (2001).
Conde, J. et al. Expanding the adipokine network in cartilage: identification and regulation of novel factors in human and murine chondrocytes. Ann. Rheum. Dis. 70, 551–559 (2011).
Maheshwari, A. et al. Epithelial cells in fetal intestine produce chemerin to recruit macrophages. Am. J. Physiol. Gastrointest. Liver Physiol. 297, G1–G10 (2009).
Catalan, V. et al. Increased adipose tissue expression of lipocalin-2 in obesity is related to inflammation and matrix metalloproteinase-2 and metalloproteinase-9 activities in humans. J. Mol. Med. 87, 803–813 (2009).
Klöting, N. et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem. Biophys. Res. Commun. 339, 430–436 (2006).
Hida, K. et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc. Natl Acad. Sci. USA 102, 10610–10615 (2005).
Ozgen, M. et al. Serum adiponectin and vaspin levels in rheumatoid arthritis. Arch. Med. Res. 41, 457–463 (2010).
Senolt, L. et al. Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. Ann. Rheum. Dis. 69, 1410–1411 (2010).
Yang, R. Z. et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metab. 290, E1253–E1261 (2006).
Schäffler, A. et al. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim. Biophys. Acta 1732, 96–102 (2005).
Acknowledgements
Part of the research described in this Review was supported by the Spanish Ministry of Health through the Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, and by the Xunta de Galicia (SERGAS). We also acknowledge the technical assistance provided by Veronica López.
Author information
Authors and Affiliations
Contributions
R. Gómez, J. Conde, M. Scotece, F. Lago and O. Gualillo researched data for the article. R. Gómez, J. J. Gómez-Reino, F. Lago and O. Gualillo contributed to discussions of the content. R. Gómez, J. Conde and O. Gualillo wrote the article. All authors performed review/editing of the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Gómez, R., Conde, J., Scotece, M. et al. What's new in our understanding of the role of adipokines in rheumatic diseases?. Nat Rev Rheumatol 7, 528–536 (2011). https://doi.org/10.1038/nrrheum.2011.107
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2011.107
This article is cited by
-
New insight into the role of lipid metabolism-related proteins in rheumatic heart valve disease
Lipids in Health and Disease (2022)
-
Adipokine human Resistin promotes obesity-associated inflammatory intervertebral disc degeneration via pro-inflammatory cytokine cascade activation
Scientific Reports (2022)
-
Treadmill running induces remodeling of the infrapatellar fat pad in an intensity-dependent manner
Journal of Orthopaedic Surgery and Research (2021)
-
Rheumatoid arthritis in Colombia: a clinical profile and prevalence from a national registry
Clinical Rheumatology (2021)
-
Obesity is associated with severe clinical course in children with Henoch-Schonlein purpura
Pediatric Nephrology (2020)